Amgen To File Panitumumab In Second-Half 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Application will seek approval for third-line treatment of colorectal cancer. Amgen says the anti-EGRF monoclonal antibody shows fewer adverse reactions than Bristol-Myers Squibb/Imclone's Erbitux.
You may also be interested in...
Amgen Raises Profile Of Oncology Therapeutics Unit
Newly promoted VP David Parkinson, MD, will oversee reconfigured oncology unit with separate supportive care and therapeutics groups.
Amgen Raises Profile Of Oncology Therapeutics Unit
Newly promoted VP David Parkinson, MD, will oversee reconfigured oncology unit with separate supportive care and therapeutics groups.
Phase III Enrollment For Amgen's Panitumumab Slowed By Erbitux Approval
Enrollment in Amgen's U.S. Phase III trial for the colon cancer agent panitumumab has substantially slowed since the launch of Bristol-Myers Squibb/ImClone's Erbitux (cetuximab)